At WOC 2018, José Cunha-Vaz (University of Coimbra, Coimbra, Portugal) discussed his experience with treating patients with DME. The most significant developments in the area of DME are OCT imaging and the availability of anti-VEGF agents, which completely revolutionised treatment. The major issue is individualising treatment to each patient, as response varies greatly between different patients. The challenge is to understand how and which patients will respond to therapies. New drugs are currently on the horizon, which will offer new and better solutions to patients.
1. What have been the most significant recent developments in the area of DME? (1:02)
2. Discuss the current unmet needs and/or the challenges you face when treating patients with DME. (2:00)
3. What developments are you most excited about in the area of DME over the next few years? (3:20)
Share this Video
Related Videos In Retina/Vitreous
David Boyer, ARVO 2023: Phase IIb RESTORE trial: MCO-010 optogenetic therapy for vision restoration in patients with retinitis pigmentosa
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]
David Boyer, ARVO 2023: Retinitis Pigmentosa and the unmet needs in its treatment
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa […]
Carl Regillo, Hawaiian Eye and Retina 2023: New and emerging treatments for neovascular age-related macular degeneration
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!